Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

Core Insights - Dyne Therapeutics is showcasing its advancements in neuromuscular disease treatments at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, with five presentations highlighting its pipeline [2][3] Group 1: DELIVER Trial Results - The DELIVER trial for z-rostudirsen in Duchenne muscular dystrophy (DMD) has shown positive topline results, indicating significant functional improvement across various muscle groups, including cardiopulmonary function [3][5] - New long-term data from the DELIVER trial will be presented, emphasizing the potential preservation of cardiopulmonary function [3][5] Group 2: Pipeline Developments - Dyne is presenting the design of a Phase 3 trial for z-basivarsen in myotonic dystrophy type 1 (DM1), which is expected to be a field-defining study [3][4] - Preclinical data for DYNE-401, aimed at addressing Pompe disease, will also be shared, demonstrating the potential for low and infrequent dosing to achieve functional improvement [4][5] Group 3: Presentation Details - The conference will feature three oral presentations, including one on the efficacy and safety of z-basivarsen in DM1 and another on the functional improvements associated with z-rostudirsen in DMD [4][6] - Poster presentations will include additional analyses from the DELIVER trial and the design of the Phase 3 trial for z-basivarsen [5][6] Group 4: Company Mission and Focus - Dyne Therapeutics is dedicated to delivering functional improvements for individuals with genetically driven neuromuscular diseases, focusing on therapies that target muscle and the central nervous system [8]